Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

Key Terms

phase ii medical

Phase II is the mid-stage clinical trial where a potential drug or medical treatment is tested in a larger group of patients to see if it works and to help determine the best dose and common side effects. For investors, Phase II results matter because they give the first meaningful evidence about effectiveness and safety—like a road test that shows whether a product has real promise before a much bigger, costly final trial and potential regulatory approval.

minimal residual disease medical

Minimal residual disease (MRD) is the tiny number of cancer cells that remain in the body after treatment, often too few to show up on standard scans but detectable with very sensitive tests. For investors, MRD is important because it predicts the risk of relapse and can determine whether a therapy is seen as effective, influences regulatory and reimbursement decisions, and affects the size and timing of a drug’s market opportunity—like spotting the last weeds that can make a garden regrow if not removed.

whole-genome sequencing medical

Whole-genome sequencing is the process of reading an organism’s entire DNA instruction manual to capture all genetic information rather than just selected parts. For investors, it matters because having the full genetic picture can reveal new diagnostics, drug targets, or personalized treatments that drive product value, regulatory approvals, and long-term revenue potential, while improvements in speed and cost can expand market reach like making a complex map easier and cheaper to produce.

molecular subtyping medical

Molecular subtyping is the classification of a disease or condition based on its underlying genes, proteins, or other molecular features rather than just visible symptoms. For investors, it matters because these finer categories can determine which patients respond to a drug or test, shaping market size, pricing, regulatory paths and the odds of commercial success—think of it like splitting a general product into precise versions that fit different customer needs.

neoadjuvant medical

"Neoadjuvant" describes treatments or interventions that are given before the main or primary procedure, such as surgery or a major decision. It’s like preparing the ground before planting seeds, aiming to improve the final outcome. For investors, understanding neoadjuvant approaches can provide insight into how companies enhance results or effectiveness in their processes or products.

More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today more than 15 abstracts featuring its urology portfolio will be presented at the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU). The abstracts span studies across prostate and bladder cancers, featuring real-world data for Decipher Prostate and new insights from phase II clinical trials, including one utilizing the company’s upcoming TrueMRD™ Muscle-Invasive Bladder Cancer (MIBC) test. Collectively, these studies highlight how Veracyte’s Decipher and TrueMRD genomic tests are increasingly helping to guide clinical decision-making, advance biological understanding, and accelerate innovation in urologic cancer care. The conference will take place February 26-28 in San Francisco.

“The breadth of data at ASCO GU shows how our Veracyte Diagnostics Platform is driving meaningful insight across multiple urologic cancers,” said Elai Davicioni, Ph.D., Veracyte’s medical director, Urology. “In bladder cancer, Decipher is increasingly being integrated into studies that aim to help guide treatment decisions. With TrueMRD, our whole-genome sequencing minimal residual disease platform, we are extending the understanding of tumor evolution and treatment resistance, while also providing critical information to ensure the earlier detection of recurrent disease when a cure may still be achievable.”

One of the key studies being presented is SURE‑02, a phase II trial examining how genomic subtyping with the Decipher Bladder test can inform treatment approaches in bladder cancer.

“The findings underscore the importance of molecular subtyping in muscle‑invasive bladder cancer and support the integration of genomic classifiers, such as the Decipher Bladder test, into clinical trial design, for the first time suggesting a biologically informed strategy for the use of anti-TROP2 ADCs,” said Andrea Necchi, M.D., principal investigator of the SURE‑02 trial. “This approach enables a more rational selection of novel treatment strategies and represents an important step in aligning clinical research with precision‑based care.”

Other highlights at the conference include an oral presentation with data on Veracyte’s upcoming TrueMRD MIBC test in the HCRN GU 20-444 response guided bladder-sparing trial and results for Decipher Bladder from NURE-combo and BLASST-01 trials:

Title:		Phase 2 trial of pembrolizumab (P) with response-guided bladder-sparing in patients with muscle-invasive bladder cancer (MIBC; HCRN GU 20-444).
Presenter:		Jonathan Anker, M.D., Ph.D., Mount Sinai Tisch Cancer Center
Format:		Rapid Oral Abstract Session
Abstract #:		737
Date/Time:		Friday, February 27, 2026, 4:00 – 4:45 PM PST
Location:		Level 3, Ballroom
Title:		Neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC): SURE-02 primary analysis and biomarker results.
Presenter:		Andrea Necchi, M.D., IRCCS San Raffaele Hospital, Comprehensive Cancer Center
Format:		Poster (#H1)
Abstract #:		769
Date/Time:		Friday, February 27, 2026, 11:30 – 12:45 PM PST
Location:		Level 1, West Hall
Title:		Association of non-luminal subtype with overall survival in high-risk non-muscle invasive bladder cancer patients: Biomarker results from the Bladder Cancer Prognosis Programme.
Presenter:		Joep J. de Jong, M.D., Erasmus MC Cancer Institute, Rotterdam, Netherlands
Format:		Poster (#K23)
Abstract #:		843
Date/Time:		Friday, February 27, 2026, 11:30 – 12:45 PM PST
Location:		Level 1, West Hall
Title:		Association between non-luminal molecular subtypes and complete response rates after neoadjuvant chemo-immune therapy for muscle-invasive bladder cancer: Biomarker analyses of NURE-combo and BLASST-01 phase 2 clinical trials.
Presenter:		Joep J. de Jong, M.D., Erasmus MC Cancer Institute, Rotterdam, Netherlands
Format:		Poster (#K25)
Abstract #:		845
Date/Time:		Friday, February 27, 2026, 11:30 – 12:45 PM PST
Location:		Level 1, West Hall

Additionally, Veracyte continues to strengthen the connection of real-world data and outcomes to the Decipher Prostate test and the Decipher Genomics Research for Intelligent Discovery (GRID) platform, with several abstracts being showcased at the conference including:

Title:		Transcriptomic characterization of prostate cancer in patients with HIV infection.
Presenter:		Michael Leapman, M.D., Department of Urology, Yale School of Medicine
Format:		Poster (#M24)
Abstract #:		396
Date/Time:		Thursday, February 26, 2026, 11:30 – 12:45 PM PST
Location:		Level 1, West Hall
Title:		Comprehensive analysis of androgen production, uptake, and conversion (APUC) genes to highlight SRD5 family diversity in a large localized prostate cancer cohort.
Presenter:		Xiaolei Shi, M.D., University of Maryland School of Medicine
Format:		Poster (#M10)
Abstract #:		382
Date/Time:		Thursday, February 26, 2026, 11:30 – 12:45 PM PST
Location:		Level 1, West Hall

Veracyte’s Decipher team will be at Booth #48 at the 2026 ASCO GU Symposium. More information, including a full list of Decipher-focused abstracts being presented, can be found here.

About Decipher Prostate

The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment. Armed with this information, physicians can better personalize their patients’ care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis. The Decipher Prostate test has been validated in many dozens of published studies involving more than 100,000 patients. It is the only gene expression test to achieve “Level 1B” evidence status and inclusion in the risk-stratification table in the most recent NCCN® Guidelines* for prostate cancer. More information about the Decipher Prostate test can be found here.

About Decipher Bladder

The Decipher Bladder Genomic Classifier is a 219-gene test, developed using RNA whole-transcriptome analysis and machine learning, that is designed for use in patients following bladder cancer diagnosis who face questions regarding treatment intensity. The test classifies bladder tumors into five molecular subtypes, each having distinct tumor biology and potential clinical implications. This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy and/or the likelihood of harboring non-organ-confined disease at time of surgery, respectively. More information about the Decipher Bladder test can be found here.

About Decipher GRID

The Decipher GRID database includes more than 200,000 whole-transcriptome profiles from patients with urologic cancers and is used by Veracyte and its partners to contribute to continued research and help advance understanding of prostate and other urologic cancers. GRID-derived information is available on a Research Use Only basis. More information about Decipher GRID can be found here.

About TrueMRD

Veracyte’s TrueMRD testing approach uniquely gives clinicians a comprehensive picture of their patient’s cancer status at every step, enabling them to personalize post-treatment care. From a small blood sample, we use AI and whole-genome sequencing to create a custom, molecular “fingerprint” for each patient’s tumor and then track the cancer’s recurrence and evolution over time. We plan to begin making our first TrueMRD test—for muscle-invasive bladder cancer—available to clinicians in the first half of 2026 and then expand to other cancers. More information about Veracyte’s TrueMRD testing approach can be found here.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to the role of Veracyte’s Decipher and TrueMRD tests in guiding clinical decision-making, advancing biological understanding, improving patient outcomes, and accelerating innovation in urologic cancer care; the anticipated clinical utility, performance, and potential impact of Decipher and TrueMRD tests; the expected benefits of whole‑genome sequencing approaches for minimal residual disease detection; and the potential impact of the Decipher GRID platform. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” "ultimately," and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 29, 2024 and our subsequent Quarterly Reports on Form 10-Q. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, and Decipher are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224172021/en/

Investors:

Shayla Gorman

investors@veracyte.com

Media:

Molly Cornbleet

media@veracyte.com

Source: Veracyte